Skip to content
Julietta Fiscella, M.D.

Julietta Fiscella, M.D.

UR Medicine Labs

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients


About Me

Dr. Fiscella is Director of Pathology, Highland Hospital Laboratories. Her clinical subspecialty interests include gyn pathology, cytopathology, pulmonary pathology, and quality assurance.

Certified Specialties

Cytopathology - American Board of Pathology

Pathology, Anatomic Pathology & Clinical Pathology - American Board of Pathology

Faculty Appointments

Clinical Associate Professor (Voluntary) - Department of Pathology and Laboratory Medicine (SMD)

Chief, Pathology, Highland Hosp Labs - Department of Pathology and Laboratory Medicine (SMD)


Residency & Fellowship

Residency, Pathology, University of Rochester Medical Center. 1992 - 1995

Residency, Pathology, University at Buffalo. 1990 - 1992

Internship, Internal Medicine, Sisters of Charity Hospital of Buffalo-GME. 1988 - 1989


MD | SUNY at Buffalo-School of Medicine & Biomedical Sciences (USA). 1988


Dr. Fiscella's research interests have included the effects of gamma interferon on pulmonary interstitial fibrosis, and the effects of mifepristone on intrauterine leiomyomas.


Journal Articles

Introducing Patients to Their Pathology Reports

Fiscella, J.

CAP Today. 2014; 28(1): 54 - 55.

Fiscella, J.; Ahmed, B.

Pathologists Can Explain Surgical Pathology to Patients:

Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone.

Fiscella J, Bonfiglio T, Winters P, Eisinger SH, Fiscella K

Human pathology.. 2011 July 42 (7):947-53. Epub 02/11/2011.

Distinguishing Features of Endometrial Pathology After Exposure to the Progesterone Receptor Modulator Mifepristone.

Fiscella, J.; Bonfiglio, T.; Winters, P.; Eisenger, S.H.; Fiscella, K.

Human Pathology. 2011; 42(7): 947-953.

Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata.

Eisinger SH, Fiscella J, Bonfiglio T, Meldrum S, Fiscella K

European journal of obstetrics, gynecology, and reproductive biology.. 2009 October 146 (2):215-8. Epub 07/07/2009.

Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata

Eisinger, S.H.; Fiscella, J.; Bonfiglio, T.; Meldrum, S.; Fiscella, K.

European Journal of Obstetrics & Gynecology and Reproductive Biology. 2009; 146: 215-218.

Eccrine porocarcinoma.

Goedde TA, Bumpers H, Fiscella J, Rao U, Karakousis CP

Journal of surgical oncology.. 1994 April 55 (4):261-4. Epub 1900 01 01.